提前2個月交付！瑞士山谷中，他們再次成功挑戰“不可能” | 逐夢者說 | Bilingual

編者按：“讓天下沒有難做的藥，難治的病”，是初心，更是愿景。自成立以來，藥明康德步履不停：從一間實驗室，到覆蓋亞洲、歐洲和北美的全球網絡。從早期的化學合成服務，到貫穿研究（R）、開發（D）和生產（M）的一體化平臺。從第一位客戶，到全球三十多個國家的數千合作伙伴。不斷發展的，是規模與能力；始終堅守的，是夢想與承諾。

致敬來時路，共譜新篇章！在這一系列訪談中，我們以“逐夢者”視角，回顧藥明康德成長發展的崢嶸歲月，回望賦能客戶創新的并肩往事，更以獨特的“藥明精神”展望未來新篇章。

十月的瑞士陽光清朗，清晨的汝拉山被一層薄霧輕柔籠罩，山林間偶爾傳來幾聲清脆的鳥鳴。在這片靜謐的山谷中，藥明康德庫威（Couvet）基地也漸漸蘇醒。

就在這份寧靜中，基地負責人杰米·安德魯斯（Jamie Andrews）接收到一封特別的郵件。發送郵件的是一位正在合作的客戶，他希望將一批關鍵臨床藥物的交付時間提前整整一個月。

留給團隊的時間被驟然壓縮了一半。

一場跨時區的項目會議迅速召開。來自歐洲與中國的研發、生產、質量、分析等團隊在線聚集。杰米在會議中語速平穩卻堅定地傳達了客戶的新需求，同時迅速制訂了新的時間表——在寧靜的汝拉山山谷里，一場與時間賽跑的競賽悄然開啟。

盡管時間縮短，一切流程卻依然有條不紊地展開。在杰米看來，這份從容源自藥明康德全球一體化CRDMO平臺的自信與底氣。

對他而言，這份沉著應對早已成為一種經過歲月打磨的本能——一種根植于他多年制藥生涯的肌肉記憶。

從汝拉山到地球村：繪制全球化網絡

杰米的職業旅程足跡遍布全球。26年前，他在澳大利亞一家公司擔任工程師，此后投身醫藥行業。隨后，他先后輾轉英國和愛爾蘭，直到2010年定居瑞士。

2021年，杰米加入藥明康德瑞士庫威基地，為自己的全球化旅程增添了嶄新一筆。

在庫威，杰米的全球背景以及國際視角，與藥明康德的全球化使命相得益彰。

從一間650平方米的實驗室起步，經過多年的發展，藥明康德在亞洲、歐洲和北美擁有二十多個研發和生產基地。從中國到新加坡，從瑞士到美國，藥明康德的CRDMO業務平臺如同一張精準編織的“分子地圖”，在不同經緯線間協同運轉。

其中，坐落在歐洲創新高地的庫威基地，在藥明康德全球CRDMO賦能平臺中扮演著重要角色。立足于當地，這個專注于制劑商業化生產和包裝的基地，正為全球多地的客戶提供賦能。

如今，藥明康德庫威基地正在為歐洲、美國、加拿大、日本、澳大利亞和新西蘭的客戶提供支持，并于近期獲得GMP認證，進一步打開巴西和土耳其等新興市場的大門。

完成“不可能的任務”

談及全球化合作時，杰米回想起一次印象深刻的經歷。

當時，杰米收到了一位客戶的請求，對方期望盡快啟動一個商業化項目。令客戶頭疼的是，某些原料在當地的采購周期漫長，按時啟動項目幾乎是一項不可能完成的任務。

當客戶抱著試試看的心態發來郵件時，杰米卻顯得從容不迫：“憑借藥明康德全球運營網絡的優勢，及時成功采購所有原料并非不可能。”

在團隊協調下，項目所需原料很快完成采購并運抵庫威。依托藥明康德的全球網絡，庫威基地提前完成了客戶“不可能的挑戰”，保證了項目的及時啟動。

這樣的故事，在杰米的記憶中屢見不鮮。

在另一次合作中，得益于與藥明康德在上海外高橋和無錫的團隊緊密合作，庫威基地快速完成技術轉移及生產等，助力客戶順利遞交了新藥申請（NDA）。這些跨區域團隊間無縫銜接的合作經歷，也讓杰米在應對各類客戶需求的時候更加信心十足。

在杰米看來，這些高效運轉的全球協作，離不開藥明康德全球一體化CRDMO模式的支持。而其中的核心理念正是“跟隨科學、跟隨客戶、跟隨分子”。

這一理念意味著，基于獨特的一體化CRDMO平臺，藥明康德能夠從分子發現之初，陪伴客戶一路走到藥物上市的終點。

例如，一個項目在藥明康德的其他基地完成了早期臨床階段開發后，可以無縫銜接到庫威基地，將項目推進到后期臨床和商業化生產階段。這種全周期、一體化的支持，能避免多環節轉移帶來的時間延誤與技術風險。

客戶對庫威基地的信任，同樣離不開藥明康德25年來長期堅守的全球質量體系。

2009年以來，藥明康德化學業務平臺成功通過全球監管機構的審計超過140次，所支持的創新藥在全球超過100個國家和地區上市。得益于出色的質量記錄，已有25次新藥上市批準前檢查（PAI，Pre-Approval Inspection）得到美國FDA和EMA豁免。

在藥明康德庫威基地，全球統一的質量標準體系確保了結果的一致性。在這里生產的產品經過包裝，可發往歐洲、北美或亞太的不同地區。

面向未來，持續建設新能力

在藥明康德的4年間，杰米親歷了庫威基地產能與能力的持續提升。例如，為了滿足持續增長的客戶需求，庫威基地新增了干法制粒、濕法制粒和OEB4高密閉設備等全新的口服固體制劑技術。

“在2024年，我們已經實現了口服制劑產能的翻倍。”杰米介紹道，2025年，庫威基地每年可生產多達20億片藥片和2.5億粒膠囊，包裝方面可支持1.5億個泡罩和1500萬瓶藥瓶。

庫威基地產能與能力拓展的步伐仍在延續。這一切，正是“為未來而建”。

在2025年9月，杰米見證著基地中一座五層新樓的封頂。這是庫威基地全新的制劑大樓，配備了噴霧干燥設備（PSD-4），預計將于2026年四季度投入運營，為全球客戶提供噴霧干燥能力——一項提升小分子口服吸收能力的關鍵技術。

未來，庫威基地還將進一步拓展賦能平臺，包括引入注射劑生產線和脂質納米粒技術，來滿足客戶多樣化需求。

在挑戰中前行

結束會議后，杰米捧起尚有余溫的咖啡，望向窗外。周圍風景依舊，汝拉山麓綠草如茵，山林間依舊有鳥兒掠過，一切又回歸到了開始的寧靜。

正如眼前的景象所映照的那樣，在全球化賦能創新的過程中，藥明康德堅定地承擔著企業社會責任，踐行可持續發展理念。

在庫威基地，屋頂的太陽能電池板每年能提供175兆瓦時的能源，足以為一部手機每天充電，長達5萬年。同時，這里的所有廢水均經過特殊處理，將對環境產生的影響降到極低；實驗室的印刷材料，也通過專業回收，進入下一個生命循環……

這些努力也得到了國際權威評級機構的認可。2024年11月，庫威基地獲得全球企業社會責任評級專業機構EcoVadis銀牌認證，在所有參與評級的公司中排名前9%。

無論是在瑞士庫威，還是全球其他基地，可持續發展理念始終貫穿了藥明康德的戰略與運營。

回到電腦前，杰米又投入到下一位客戶的項目中。對他來說，這次挑戰是作為庫威基地負責人日常工作的一個縮影。在藥明康德，挑戰并不罕見。它們更像是一場場新的冒險，帶來新的經歷和突破。

偶爾，杰米也會回想過去的工作。那時，他的整個職業生涯或許只會追隨一兩個分子的研發到市場化工作。而如今，他的日常是每天都在努力幫助客戶將各種分子的開發加速推進，為患者帶來更多創新藥物。

“這是我真正的動力，早日實現‘讓天下沒有難做的藥，難治的病’的偉大愿景。”杰米說。

At Couvet, Speed has an Address

Editor’s Note: “Every drug can be made and every disease can be treated”. Since 2000, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to thousands of partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision.

In tribute to the journey, we look back through the eyes of our “dream-makers”: revisiting the stories of partnership that empowered global innovation, and the unique spirit that continues to guide us toward the next chapter.

On a crisp, sunny October morning in Couvet, Switzerland, a request comes into Jamie Andrews’ phone: a client needs a critical clinical batch one month earlier than scheduled; the new deadline is in just four weeks.

Within hours, Andrews has quality, analytical, and project teams in Europe and China moving in parallel. As one team drafts protocols, another pulls testing windows forward and untangles the supply paths.

“There’s always a way to get things done,” Andrews says. For the head of WuXi AppTec’s Couvet site, that steady composure is built from a career of hopping hemispheres and stitching together production lines that span continents.

A Global Life, a Global Mandate

Andrews began his career in Australia, trained as an engineer. More than 20 years in pharma took him from Australia to England, Ireland, and finally Switzerland in 2010. He joined WuXi AppTec in 2021, bringing a distinctly international lens, borne from a career spent reading problems from multiple time zones at once.

His global background matters because Couvet’s daily work is international by design. Set in the center of Europe, the site supports clients across Europe, the U.S., Canada, Japan, Australia, New Zealand, and beyond, and has recently added GMP certifications that open doors in markets such as Brazil and Turkey. It is the hub for manufacturing, packaging, and testing late-stage clinical and commercial oral solid drug products, plugged directly into WuXi AppTec’s “follow the molecule” network from discovery to launch. “We enhance supply chain flexibility for our clients, providing a cost-effective option to deliver high-quality drug products to patients worldwide,” Andrews says.

Behind that reach are capacity and capability. “There’s already been significant investment at our site,” Andrews says. In recent years, the site has installed new oral-solid-dosage technologies such as dry granulation, wet granulation, and OEB4 high-containment equipment to support a broader range of client needs.

“Additionally, we have doubled manufacturing and packaging capacities,” he continues. In 2025, the lines can turn out up to 2 billion tablets and 250 million capsules a year, and package 150 million blister packs, plus 15 million bottles annually.

A Global CRDMO for Global Customers

Couvet’s advantage lies in how it operates within WuXi AppTec’s global CRDMO system (Contract Research, Development, and Manufacturing Organization). “Our customers like to work with one company,” Andrews says. “Often, after partnering with other WuXi AppTec teams in early clinical stages, they are ready to commercialize, and that is where our site comes in.” By completing journeys that begin at sister sites around the world, Couvet delivers products through global synergy and a seamless handover.

Andrews points to two moments that show how the network supports clients in complex projects. In one program, a client was preparing a commercial launch of a complex product, and sourcing key materials on time was challenging. Few vendors could deliver within the window.

“By leveraging the strength of our global network, we were able to successfully secure all the materials and keep the project on track.” Andrews said. A team in Shanghai secured the materials quickly, while a project management team streamlined activities in parallel, so no step idled in the middle.

With the support, the Couvet site delivered the results ahead of expectation. “That allowed us to meet the client’s launch schedule and most importantly, deliver the drug products to patients without delay.” Andrews says.

In another example, teams across Shanghai, Wuxi City, and Couvet collaborated closely, quickly aligned the manufacturing process and completed an NDA submission successfully.

According to Andrews, this is why customers increasingly seek partners with a true global footprint, not just a single manufacturing location but multiple qualified sites around the world, so that supply is resilient and secure.

Global Spirit, Locally Established

Serving globally is easier said than done. At Couvet, a single bulk batch can be packaged and released for Europe, North America, or Asia Pacific. A harmonized global quality system keeps outcomes consistent. “We have the same policies, the same procedures, the same document management systems across all our sites to ensure we produce the same high level of quality,” Andrews said, “and, most importantly, to protect patient safety.”

To Andrews, however, global reach does not mean losing sight of local roots. Originally a commercial manufacturing site within a large pharmaceutical company, the Couvet site built a strong quality track record with European authorities and the FDA, and it has maintained excellence in commercial manufacturing.

From Andrews’s window, the Jura Mountains roll away into green grass and forest. Environmental stewardship matters in Switzerland, and it shows in his team’s operations. The site integrates sustainability into daily practice, generating 175 MWh of renewable energy annually from rooftop solar panels, enough to charge a mobile phone every day for 50,000 years. Alongside wastewater treatment and materials recycling, the site earned a Silver EcoVadis medal, placing it in the top 9% of rated companies.

It also stays close to its community, from engaging local suppliers on expansion projects to turning the company Christmas party into a small marketplace where regional artisans and producers were invited to sell their goods. “We are part of an ecosystem here,” Andrews says. “We try to contribute to it.”

Building for What’s Next

The next chapter at Couvet is already framed in scaffolding. Just beyond the packaging halls, crews are installing a commercial PSD-4 spray-drying suite built for the kind of tricky, low-solubility compounds that clients increasingly ask for. The structure is slated to be operational in Q4 2026. Looking further ahead: Andrews’ team is laying the groundwork for parenteral drug-product capabilities, including injectable manufacturing lines and lipid-nanoparticle technologies, so a client can move from tablets and capsules to sterile formats without leaving the WuXi AppTec global enabling platform.

Scale is another multiplier. Having doubled manufacturing and packaging capacity, Couvet can absorb programs with heavier volume profiles and give clients room to ramp a launch, to ride demand spikes, to consolidate supply under one roof.

“One of the things I really appreciate about working at WuXi AppTec is the challenge that comes every day. It's like being on an adventure. I am doing different things every day.” Andrews says. “That's my day-to-day job, bringing innovative products to patients. That's what really motivates me.”

免責聲明：本文 僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療 方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。